Infections in the bladder or urinary system can irritate the prostate and cause inflammation that increases PSA. A urinary tract infection can also raise PSA levels, even if the prostate itself is not directly infected. Once the infection or inflammation improves, PSA levels often return to normal within a few weeks. If PSA changes slowly and the patient’s symptoms fit with BPH, doctors usually monitor the situation rather than immediately performing a biopsy. The possibility of a significant relationship between testosterone, testosterone replacement and LUTS/BPH mandate the urologist consider these factors when patients are being investigated for LUTS. Vignozzi et al.42 showed the presence of prostate and bladder inflammation in rabbits with metabolic syndrome; this inflammation was exacerbated when the rabbits were made hypogonadal and returned to baseline when they were treated with testosterone. This is not a new concept; as early as 1939, Walther and Willoughby33 used testosterone to treat 15 men with "BPH" with the improvement in their LUTS over 2 years; although this treatment seemed to have been dismissed or forgotten for some time. TRT, when given to appropriately selected patients with vigilant monitoring as outlined in this review and in Table 1, can bring improvements in quality-of-life, energy level, libido, muscle mass, cognition and bone density. With vigilant monitoring of serum estrogen levels, TRT has been shown to promote weight loss. Aside from frequent monitoring of congestive symptoms and peripheral edema in this select population, TRT appears to be safe for patients with chronic kidney disease without dose adjustment. Few studies have assessed the effects of TRT in patients with chronic kidney disease; however, small studies have suggested that TRT has anabolic effects among ESRD patients, even in the absence of hypogonadism. Furthermore, the half-life of testosterone elimination after withdrawal appears similar between patients with and without ESRD. Because TRT is known to cause water retention, caution with testosterone use in patients with chronic renal insufficiency is often advised. While topical testosterone delivery systems avoid first-pass hepatic metabolism, there remains concern regarding TRT in patients with chronic liver disease. By working closely with your healthcare provider, you can address any concerns promptly and maintain both your testosterone levels and prostate health in balance. If a man already has prostate cancer or is at high risk, doctors may be more cautious about prescribing TRT. If your PSA levels rise significantly, your doctor may recommend further tests to rule out prostate cancer or other conditions. However, because the prostate uses testosterone, there's a worry that increasing testosterone levels through TRT might stimulate the growth of prostate cancer cells. The decision to proceed with TRT should be made on a case-by-case basis, considering individual risk factors and potential benefits. Monitoring PSA levels during TRT helps to detect any potential issues early on. PSA stands for Prostate-Specific Antigen, a protein produced by the prostate gland. As discussed, the key issue is the potential to accelerate the growth of existing cancer, not to induce the formation of new cancerous cells. TRT is often used to treat hypogonadism, a condition where the body doesn’t produce enough testosterone. The goal is to offer clear and understandable information that will help you make informed decisions about your health. This article aims to provide a comprehensive guide to the relationship between TRT and PSA levels. One area of concern is its potential impact on the prostate, particularly regarding a protein called Prostate-Specific Antigen (PSA). Finally, DIM may also aid in reducing sex hormone-binding globulin (SHBG), which may help increase the availability of free testosterone. Recent preclinical research shows that DIM promotes the formation of more favorable estrogen metabolites by inducing CYP enzymes, and may help support a healthier balance between testosterone and estrogen by reducing aromatization. DHT is a more potent androgen that activates the androgen receptor and increases PSA expression in prostate cells. While testosterone does not directly cause the formation of cancerous cells, it can act as a fuel for existing cancer cells. Seven to nine hours of consistent sleep can increase testosterone and improve GH/IGF‑1 signaling.
